PROSPECTUS SUPPLEMENT
(To Prospectus dated June 22, 2020)
![LOGO](https://capedge.com/proxy/424B5/0001193125-20-198030/g42955g12r91.jpg)
Common Stock
Having an Aggregate Offering Price of Up to
$1,000,000,000
This prospectus supplement and the accompanying base prospectus relate to the offer and sale from time to time of shares of our common stock, par value $0.01 per share, in an amount having an aggregate offering price of up to $1,000,000,000 through the managers named in this prospectus supplement acting as sales agents or principals, or, if applicable, as Forward Sellers (as defined below) acting as agents or principals of the Forward Purchasers. These sales, if any, will be made pursuant to the terms of an equity distribution agreement among us and the managers, and, as applicable, the relevant Forward Purchasers, which was filed with the Securities and Exchange Commission on July 23, 2020 as an exhibit to a Current Report on Form 8-K (the “Equity Distribution Agreement”).
Under the terms of the Equity Distribution Agreement, we also may sell our common stock to any manager as principal for its own account at a price agreed upon at the time of the sale. If we sell our common stock to any such manager as principal, we will enter into a separate terms agreement with that manager and we will describe that agreement in a separate prospectus supplement or pricing supplement.
The Equity Distribution Agreement contemplates that, in addition to the issuance and sale by us of shares of our common stock to or through the managers as our sales agents, we may enter into separate forward sale agreements (each, together with any related pricing supplement, a “forward sale agreement” and, collectively, the “forward sale agreements”), with certain of the managers, or one of their respective affiliates (in such capacity, each, a “Forward Purchaser” and, collectively, the “Forward Purchasers”). If we enter into a forward sale agreement with any Forward Purchaser, we expect that such Forward Purchaser, acting in accordance with the mutually accepted instructions related to such forward sale agreement, will attempt to borrow and sell, through the relevant manager, acting as agent for such Forward Purchaser, shares of our common stock to hedge such Forward Purchaser’s exposure under such forward sale agreement. We refer to a manager, when acting as agent or principal for the relevant Forward Purchaser, as, individually, a “Forward Seller” and, collectively, the “Forward Sellers.” Each Forward Purchaser will be either one of the managers named in this prospectus supplement or an affiliate of one of those managers and, unless otherwise expressly stated or the context otherwise requires, references herein to the “related” or “relevant” Forward Purchaser mean, with respect to any manager, the affiliate of such manager that is acting as Forward Purchaser or, if applicable, such manager acting in its capacity as Forward Purchaser. We will not initially receive any proceeds from any sale of shares of our common stock borrowed by a Forward Purchaser and sold through a Forward Seller.
We currently expect to fully physically settle each forward sale agreement, if any, with the relevant Forward Purchaser on one or more dates specified by us on or prior to the maturity date of such forward sale agreement. However, subject to certain exceptions, we may also elect, in our sole discretion, to cash settle or net share settle all or any portion of our obligations under any forward sale agreement, in which case we may not receive any proceeds (in the case of cash settlement) or will not receive any proceeds (in the case of net share settlement), and we may owe cash (in the case of cash settlement) or shares of our common stock (in the case of net share settlement) to the relevant Forward Purchaser. See “Plan of Distribution.”
Our common stock is listed on the New York Stock Exchange (the “NYSE”), under the symbol “OKE.” The last reported sale price of our common stock on July 21, 2020 was $29.98 per share.
Sales of our common stock under this prospectus supplement, if any, will be made from time to time by means of ordinary brokers’ transactions through the facilities of the NYSE at market prices, in block transactions, or as otherwise agreed among us and the managers, as our sales agents or as Forward Sellers, by means of any other existing trading market for our common stock or to or through a market maker other than on an exchange. We or any of the managers may suspend the offering of common stock at any time and from time to time by notifying the other party. The offering of the shares is subject to receipt and acceptance and subject to the managers’ right to reject any order in whole or in part.
Investing in our common stock involves a high degree of risk. Before buying any common stock, you should read the discussion of material risks of investing in our common stock in “Risk Factors” beginning on page S-5 of this prospectus supplement, on page 7 of the accompanying base prospectus and the other risks identified in the documents incorporated by reference herein before making a decision to purchase our common stock in this offering.
The compensation to each manager for sales of common stock under this prospectus supplement shall be up to, but shall not exceed, 2.0% of the gross sale price of common stock sold by such manager. The compensation to each manager acting as a Forward Seller will be a mutually agreed commission in the form of a reduction to the initial forward price under the related forward sale agreement that shall be up to, but shall not exceed 2.0% of the gross sales price of the borrowed shares of our common stock sold through such manager, acting as Forward Seller, during the applicable forward hedge selling period for such shares (which gross sales price will be adjusted for daily accruals based on a floating interest rate, less a spread, and specified amounts related to expected dividends on shares of our common stock if an “ex-dividend” date occurs during such forward hedge selling period). Please read “Plan of Distribution” in this prospectus supplement. The net proceeds we receive from any sales under this prospectus supplement will be used as described under “Use of Proceeds” in this prospectus supplement. The common stock to which this prospectus supplement relates will be sold through only one manager, as our sales agent or as a Forward Seller, on any given day.
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| | | | | | |
Credit Suisse | | BofA Securities | | Goldman Sachs & Co. LLC | | Mizuho Securities |
| | | |
Morgan Stanley | | RBC Capital Markets | | Scotiabank | | SMBC Nikko |
| |
SunTrust Robinson Humphrey | | TD Securities |
Prospectus Supplement dated July 23, 2020.